Autonomix Medical, Inc.

Autonomix Medical, Inc. is a development-stage medical device company focused on creating innovative technologies for sensing and treating disorders related to the nervous system. The company's core technology platform features a catheter-based microchip-enabled sensing array designed to detect and differentiate neural signals with high sensitivity, as demonstrated in animal studies. This technology is initially being developed for patients suffering from pancreatic cancer pain, a condition identified as having a significant unmet medical need. The company's business model is centered on the development and eventual sale of single-use disposable catheters to existing hospital catheter labs, with revenue volume expected to be a direct function of the number of procedures performed. The company operates as a pre-revenue, clinical stage life sciences entity and has incurred significant losses since its inception, with no product sales revenue to date.

The company's technology is divided into two main development parts: diagnostic sensing and therapeutic radiofrequency ablation. The diagnostic sensing component aims to precisely identify disorder-related neuronal activity to enable targeted therapy. The Autonomix system is designed to have signal detection thresholds below 5 µV, with prototype electrode dimensions as small as approximately 0.02 mm by 0.03 mm, indicating substantially higher sensitivity compared to currently marketed devices like the Boston Scientific Orion device, which has a signal detection threshold of approximately 10 µV with electrode dimensions of roughly 0.4 mm by 0.5 mm. This enhanced sensitivity, if validated in clinical trials, could enable novel transvascular nerve targeting, treatment, and confirmation across various neurological conditions. The therapeutic component involves radiofrequency ablation, which has successfully demonstrated in animal models the ability to identify a specific nerve bundle signal before ablation and confirm its termination after treatment.

The company's initial focus for commercialization is on pancreatic cancer pain management due to the significant unmet need, with 90% of pancreatic cancer patients reporting pain to their healthcare providers and 50% reporting emergency room visits for pain-related symptoms. The global market for pancreatic cancer treatment was estimated at $2.2 billion ¹ in 2022. The company believes its technology, if cleared for pancreatic cancer pain, could eventually expand to include pain from pancreatitis, which has an incidence three times that of pancreatic cancer. Beyond pancreatic cancer, the platform has potential applications in chronic pain management from all causes, hypertension, cardiovascular disease, and other nerve-related disorders, with the broader electrophysiology market estimated at $6.8 billion ² in 2021 and projected to reach $11.6 billion ³ by 2027. The company estimates its platform could address over $100 billion ⁴ in market opportunities when including indications like COPD, irritable bowel syndrome, and overactive bladder.

For the fiscal year ended March 31, 2025, Autonomix Medical, Inc. reported a net loss of $11.4 million ⁵, an improvement from a net loss of $15.4 million ⁶ for the year ended March 31, 2024. Total operating expenses decreased by $0.442 million ⁷, or -4% ⁸, from $12.030 million ⁹ in 2024 to $11.588 million ¹⁰ in 2025. This was primarily driven by the absence of a $4.556 million ¹¹ warrant expense related to a termination agreement in 2025, which was present in 2024. Research and development (R&D) expenses increased significantly by $2.5 million ¹², or 112% ¹³, from $2.225 million ¹⁴ in 2024 to $4.725 million ¹⁵ in 2025, primarily due to clinical trial execution and product development costs. General and administrative (G&A) expenses increased by $1.6 million ¹⁶, or 31% ¹⁷, from $5.249 million ¹⁸ in 2024 to $6.863 million ¹⁹ in 2025, mainly due to increases in officer and employee compensation and benefits of $1.5 million ²⁰, stock-based compensation of $0.9 million ²¹, legal and professional fees of $0.4 million ²², insurance expense of $0.3 million ²³, franchise tax of $0.3 million ²⁴, and board of directors compensation of $0.1 million ²⁵, partially offset by a decrease in advertising expense of $1.8 million ²⁶ related to the 2024 IPO and travel and entertainment expense of $0.1 million ²⁷.

The company's cash and cash equivalents stood at $9.136 million ²⁸ as of March 31, 2025, up from $8.608 million ²⁹ as of March 31, 2024. Working capital as of March 31, 2025, was $7.9 million ³⁰. Net cash used in operating activities was $8.258 million ³¹ for the year ended March 31, 2025, compared to $6.648 million ³² for the prior year. Cash provided by financing activities was $8.8 million ³³ in 2025, primarily from gross proceeds of approximately $10.0 million ³⁴ from a November 2024 underwritten public offering, offset by $1.1 million ³⁵ in issuance costs for this offering and $0.2 million ³⁶ for a subsequent registration statement. This compares to $14.4 million ³⁷ in financing activities in 2024, which included $10.9 million ³⁸ from an IPO, $2.8 million ³⁹ from a private placement, and $2.0 million ⁴⁰ from convertible notes. The company's accumulated deficit as of March 31, 2025, was $50.4 million ⁴¹.

During the reported period, Autonomix completed its initial trial phase of its first-in-human proof-of-concept trial ("PoC 1") evaluating the safety and effectiveness of delivering transvascular energy to ablate problematic nerves and mitigate pain in pancreatic cancer patients. Positive results from PoC 1 led to an expansion into a follow-on phase ("PoC 2"), now including pain management for additional visceral cancers (gall bladder, liver, and bile duct) and earlier-stage pancreatic cancer patients with moderate to severe pain. The company also entered into a license agreement with RF Innovations, Inc. (RFI) on July 10, 2024, for a perpetual non-exclusive worldwide royalty-free fully paid license related to RFI's Apex 6 Radiofrequency Generator, issuing 12,500 ⁴² unregistered shares of common stock valued at $0.1 million ⁴³ as consideration. A one-for-twenty reverse stock split ⁴⁴ was completed on October 24, 2024. The company also entered into an At Market Issuances Sales Agreement (ATM Agreement) on February 28, 2025, to sell up to $2.1 million ⁴⁵ in common stock, having sold 800 ⁴⁶ shares for net proceeds of approximately $1,746 ⁴⁷ as of March 31, 2025.

Autonomix Medical, Inc. estimates its current cash resources are sufficient to fund operations into but not beyond the first calendar quarter of 2026 ⁴⁸. The company will require additional financing in the range of $32 million to $40 million ⁴⁹ to fund its operations through initial commercial launch. If unable to raise sufficient funds, the company will be required to develop and implement an alternative plan to further extend payables, reduce overhead, or scale back its business plan until sufficient additional capital is raised.

The company's primary growth area is the continued development and commercialization of its catheter-based microchip-enabled sensing array and therapeutic radiofrequency ablation technology. The initial focus remains on pain management for pancreatic cancer patients, with the intent to bring sensing and treatment together in a future pivotal clinical trial for commercial launch. Following positive results from PoC 1, the company has expanded its protocol into PoC 2, which includes pain management for additional visceral cancers such as gall bladder, liver, and bile duct, as well as earlier-stage pancreatic cancer patients experiencing moderate to severe pain. This market expansion opportunity has the potential to double the addressable market beyond pancreatic cancer pain. The company believes success in pancreatic cancer pain management will be indicative of the system's potential in a wide range of disorders involving the peripheral nervous system, including renal denervation for hypertension, other sources of pain (lower back, joints, Complex Regional Pain Syndrome, pelvic pain), pulmonary disorders (chronic obstructive pulmonary disease), and urinary tract and digestive disorders. The company's vision is to expand electrophysiology beyond cardiology to nearly all reaches of the peripheral nervous system, ultimately resulting in a market opportunity much greater than current projections for the electrophysiology market, which was estimated at $6.8 billion ⁵⁰ in 2021 and is expected to reach $11.6 billion ⁵¹ by 2027. The company believes enabling targeted transvascular treatment of pain will allow access to the $75 billion ⁵² pain management market, and facilitating safer renal denervation could access the $23 billion ⁵³ hypertension market, with the overall platform potentially addressing over $100 billion ⁵⁴ in market opportunities.

Operationally, the company expects to incur increased research and development costs in the future as it advances its product into and through clinical trials, pursues additional regulatory approvals in the United States, and continues commercial development of its devices. The company is actively engaged with the FDA through the pre-submission process for U.S.-based IDE clinical trials, intending to start with a small, single-site Early Feasibility Study (EFS) leading into a larger, multi-centered pivotal trial. The first PoC trial in Europe is not designed to replace the pivotal trial required by the FDA but to provide key learnings and procedural knowledge. The company's technology development plan involves three distinct phases: sensing, ablation, and the combination of these two technologies into an integrated device. The human clinical version of the sensing device is expected to be completed in 2026 ⁵⁵, with the commercial scale-up process completed by mid-2027 ⁵⁶. The company is incorporating learnings from its current "blind" PoC trial, which uses off-the-shelf RF ablation systems, into the design of a customized RF catheter for its own therapeutic device.

Planned capital allocation includes continued significant spending on scientific and product research and development, product testing, preclinical and clinical investigation, and intellectual property development and prosecution. The company's revenue model is envisioned on several levels: as a targeted therapy for pancreatic tumors and pancreatitis, as a standalone sensing technology for broad diagnostics or use with other ablation systems, or as a combined sensing and ablation system for a wide array of disorders. The primary revenue model is expected to be the sale of single-use disposable catheters to existing hospital catheter labs. The company has 18 patent families ⁵⁷ comprising 86 ⁵⁸ issued patents (41 ⁵⁹ in the US) and 41 ⁶⁰ pending patent applications, with expiration dates ranging from 2033 to 2039 ⁶¹.

The company explicitly flags several structural headwinds and execution risks. The timing and costs of clinical trials are difficult to predict and trial plans may change, making current estimates potentially inaccurate. There is no guarantee that regulatory authorities will approve trial designs or that the FDA will accept data from international trials, potentially requiring additional costly and time-consuming Early Feasibility Studies. The company also highlights the challenge of scaling up from its existing hand-built sensing prototype to a robust commercial version, with no assurance of successful commercial-scale production. Furthermore, the company is a development-stage entity with no approved products and no history of generating revenue, raising substantial doubt about its ability to continue as a going concern without additional financing.

Autonomix Medical, Inc. faces substantial risks, including its ability to continue as a going concern, given an accumulated deficit of $50.4 million ⁶², negative cash flows from operating activities of $8.3 million ⁶³, and working capital of $7.9 million ⁶⁴ as of March 31, 2025. The company has no approved products and cannot assure future revenue or profitability, requiring additional financing of $32 million to $40 million ⁶⁵ to fund operations through initial commercial launch. Operational risks include reliance on a single manufacturer for its lead product candidate, which could lead to supply disruptions, inability to meet demand, or difficulties in modifying production lines. The company has limited experience in assembling and testing products on a commercial scale, posing risks to meeting regulatory requirements and achieving acceptable costs. Rapidly changing technology in the life sciences industry could render its products obsolete. Regulatory risks are significant, as there is no guarantee the FDA will grant 510(k) or de novo clearance or PMA approval for future products, and modifications may require new clearances. The results of future clinical trials may not support product claims or could reveal adverse side effects, and the FDA may not accept data from international trials. Intellectual property risks include potential claims of infringement by third parties, the possibility that existing patents may be too narrow, and challenges in protecting IP rights globally. Cybersecurity risks are present due to reliance on third-party cloud-based service providers, with potential for system failures, cyberattacks, and data breaches impacting operations, intellectual property, and patient data.

Management's message to shareholders emphasizes the company's position as a development-stage medical device company focused on innovative technologies for sensing and treating nervous system disorders, with an initial focus on pancreatic cancer pain. They highlight the first-in-class catheter-based microchip-enabled sensing array, which has demonstrated high sensitivity in animal studies. Management explicitly states that the company has no source of product sales revenue ⁶⁶ and expects to continue incurring significant operating losses and negative cash flow for the foreseeable future. They project that current cash resources are sufficient to fund operations into but not beyond the first calendar quarter of 2026 ⁶⁷, and estimate requiring additional financing in the range of $32 million to $40 million ⁶⁸ to fund operations through initial commercial launch. The three strategic priorities emphasized are advancing the diagnostic sensing technology to meet human use standards, expanding the proof-of-concept trial (PoC 2) to include additional visceral cancers and earlier-stage pancreatic cancer patients, and actively engaging with the FDA through the pre-submission process for U.S.-based IDE clinical trials, with an ultimate FDA clearance anticipated in 2027 ⁶⁹.